Copyright
©The Author(s) 2024.
World J Hepatol. Jan 27, 2024; 16(1): 91-102
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.91
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.91
Table 1 Baseline characteristics of patients with advanced hepatocellular carcinoma receiving sorafenib with or without add-on transcatheter arterial chemoembolization
| Ref. | Study design | Group | Number of cases | Age1 (yr) | Male | ECOG-PS | BCLC stage | Child-Pugh class | AFP | PVTT | |||||
| 0 | 1-2 | A | B | C | A | B | |||||||||
| Koch et al[19], 2021 | Retrospective cohort study | Sorafenib + TACE | 54 | 64 (34-77) | 47 (87) | 16 (30) | 38 (70) | 0 (0) | 0 (0) | 54 (100) | 40 (74) | 14 (26) | < 400 ng/mL; 36 (66) | ≥ 400 ng/mL; 18 (34) | 18 (33) |
| Sorafenib alone | 82 | 66 (28-85) | 72 (88) | 37 (45) | 45 (55) | 0 (0) | 0 (0) | 82 (100) | 61 (74) | 21 (26) | 52 (64) | 30 (36) | 27 (33) | ||
| Park et al[20], 2019 | Multi-center RCT phase III | Sorafenib + TACE | 170 | 60 ± 10 | 136 (80) | 136 (80) | 34 (20) | 3 (2) | 39 (23) | 128 (75) | 148 (87) | 22 (13) | < 200 ng/mL; 79 (47) | ≥ 200 ng/mL; 91 (54) | 68 (40) |
| Sorafenib alone | 169 | 61 ± 10 | 147 (87) | 140 (83) | 29 (17) | 0 (0) | 44 (26) | 125 (74) | 147 (87) | 22 (13) | 76 (45) | 93 (55) | 63 (37) | ||
| Kok et al[23], 2019 | Retrospective cohort study | Sorafenib + TACE | 426 | 60 (51-69) | 355 (83) | NA | 0 (0) | 0 (0) | 426 (100) | 426 (100) | 0 (0) | NA | NA | ||
| Sorafenib alone | 1686 | 60 (52-68) | 1410 (84) | NA | 0 (0) | 0 (0) | 1686(100) | 1686 (100) | 0 (0) | NA | NA | ||||
| Wu et al[21], 2017 | Retrospective study | Sorafenib + TACE | 56 | 50 ± 12 | 48 (86) | NA | 0 (0) | 10 (18) | 46 (82) | 45 (80) | 11 (20) | < 400 ng/mL; 33 (59) | ≥ 400 ng/mL; 23 (41) | 32 (57) | |
| Sorafenib alone | 48 | 48 ± 13 | 46 (96) | NA | 0 (0) | 16 (33) | 32 (67) | 46 (96) | 2 (4) | 23 (49) | 24 (51) | 24 (50) | |||
| Zhang et al[22], 2015 | Retrospective study | Sorafenib + TACE | 45 | 50 ± 9 | 43 (96) | 45 (100) | NA | 34 (76) | 11 (24) | < 200 ng/mL; 3 (7) | ≥ 200 ng/mL; 42 (93) | 45 (100) | |||
| Sorafenib alone | 44 | 54 ± 10 | 41 (93) | 44 (100) | NA | 34 (77) | 10 (23) | 9 (20) | 35 (80) | 44 (100) | |||||
- Citation: Yang HJ, Ye B, Liao JX, Lei L, Chen K. Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2024; 16(1): 91-102
- URL: https://www.wjgnet.com/1948-5182/full/v16/i1/91.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i1.91